InterCure Provides an Update Regarding Nir Oz Facility
2024年2月14日 - 6:46AM
InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc)
("
InterCure" or the
"
Company"), the leading medical
cannabis company in Israel and outside of North America, reports
today that, further to the Company’s press release issued on
October 17, 2023, in which the Company provided an update regarding
the status of the security situation in Israel, and its impact on
the Company and its employees, the Company is providing an
additional update regarding the status of its facility in Kibbutz
Nir Oz (the “
Southern Israel Site”).
Since October 7, 2023, war situation was
declared by the Israeli government. As of this date, there is
limited access to the Southern Israel Site, and parts of the site
are being used by the Israel Defense Forces (the
“IDF”), including, among others, the IDF’s medical
corps.
The Company has begun the process of restoring
the Southern Israel Site, and the restoring efforts are advancing
according to its plans. In addition, the Company is working
diligently with the Israeli authorities to obtain full compensation
for the damages caused by the terrorist attack and the war in Gaza.
The Company believes, with high certainty, that it will be entitled
for compensation from the Israeli Governmental authorities for all
direct and indirect damages suffered, as stated in the Company’s
press release issued on October 17, 2023.
With the leadership position in the medical
cannabis market and years of operations with the community of
Kibbutz Nir-Oz, the Company is committed to restore and further
develop the Southern Israel Site. The Company is also committed to
support patients’ communities especially, patients living in
affected and evacuated areas, casualties and IDF veterans. Bringing
relief is our mission statement.
Intercure is thankful to its managers and
employees for their commitment and to its strategic partners in
Israel and worldwide who stand with us in this war time.
The Company intends to file preliminary results
for the second half of 2023 and for its full year of 2023 through
the beginning of March, and to file its full financial results for
2023 during April 2024.
About InterCure
(dba
Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TASE:
INCR) is the leading, profitable, and fastest growing cannabis
company outside of North America. Canndoc, a wholly owned
subsidiary of InterCure, is Israel’s largest licensed cannabis
producer and one of the first to offer Good Manufacturing Practices
(GMP) certified and pharmaceutical-grade medical cannabis products.
InterCure leverages its market leading distribution network, best
in class international partnerships and a high-margin vertically
integrated "seed-to-sale" model to lead the fastest growing
cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Forward‐Looking
Statements
This press release may contain forward-looking
statements. Forward-looking statements may include, but are not
limited to, statements relating to the security events in Israel,
as well as statements, other than historical facts, that address
activities, events or developments that InterCure intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
“believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause InterCure’s actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company’s success of its global
expansion plans, its continued growth, the expected operations,
financial results business strategy, competitive strengths, goals
and expansion and growth plans, expansion strategy to major markets
worldwide, the impact of the COVID-19 pandemic, the impact of the
war in Israel and the war in Ukraine and the conditions of the
markets generally. Forward-looking information is based on a number
of assumptions and is subject to a number of risks and
uncertainties, many of which are beyond InterCure’s control, which
could cause actual results and events to differ materially from
those that are disclosed in or implied by such forward-looking
information. Such risks and uncertainties include, but are not
limited to: changes in general economic, business and political
conditions, changes in applicable laws, the U.S. regulatory
landscapes and enforcement related to cannabis, changes in public
opinion and perception of the cannabis industry, reliance on the
expertise and judgment of senior management, as well as the factors
discussed under the heading “Risk Factors” in InterCure’s Annual
Information Form dated March 31, 2023, which is available on SEDAR
at www.sedar.com, and under the heading “Risk Factors” and
“Cautionary Note Regarding Forward-Looking Statements” in the
registration statement on Form 20-F, filed with the Securities
Exchange Commission on May 1, 2023. InterCure undertakes no
obligation to update such forward-looking information, whether as a
result of new information, future events or otherwise, except as
expressly required by applicable law.
Contact:
InterCure Ltd.Amos Cohen, Chief Financial
Officeramos@intercure.co
Intercure (NASDAQ:INCR)
過去 株価チャート
から 4 2024 まで 5 2024
Intercure (NASDAQ:INCR)
過去 株価チャート
から 5 2023 まで 5 2024